1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsancient DNA for Modern Genomics (aDMG) Coordination Center is sponsored by National Institutes of Health. ancient DNA for Modern Genomics (aDMG) Coordination Center is a forecasted funding opportunity on Grants.
Get alerted about grants like this
Save a search for “National Institutes of Health” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
A **. gov** website belongs to an official government organization in the United States.
* How to Apply for Grants * **Applicant Resources** * Adobe Software Compatibility * Submitting UTF-8 Special Characters * Encountering Error Messages * Grantor Standard Language * Submitting UTF-8 Special Characters * **Applicant System-To-System** * Reference Implementation * **Grantor System-To-System** * Reference Implementation * SF-424 Individual Family * SF-424 Mandatory Family * SF-424 Short Organization Family * Post-Award Reporting Forms * Country and State Lists Updates * **Manage Subscriptions** * Program Management Office * Grants.
gov Maintenance Calendar # View Grant Opportunity Forecast ancient DNA for Modern Genomics (aDMG) Coordination Center Department of Health and Human Services National Institutes of Health Note: This is a Forecasted Opportunity.
Document Type:Grants Notice Opportunity Number:FOR-HG-26-004 Opportunity Title:ancient DNA for Modern Genomics (aDMG) Coordination Center Opportunity Category:Discretionary Opportunity Category Explanation: Funding Instrument Type:Cooperative Agreement Category of Funding Activity:Health Expected Number of Awards:1 Assistance Listings:93.
172 -- Human Genome Research Cost Sharing or Matching Requirement:No Forecasted Date:Jul 15, 2025 Last Updated Date:Jul 15, 2025 Estimated Post Date:Dec 01, 2025 Estimated Application Due Date:Mar 02, 2026 Estimated Award Date:Oct 30, 2026 Estimated Project Start Date:Oct 30, 2026 Estimated Total Program Funding:$ 1,500,000 Eligible Applicants:County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Native American tribal governments (Federally recognized) Private institutions of higher education For profit organizations other than small businesses Public housing authorities/Indian housing authorities Public and State controlled institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Additional Information on Eligibility: ## Additional Information Agency Name:National Institutes of Health Description:The National Human Genome Research Institute (NHGRI) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications to establish an ancient DNA for Modern Genomics (aDMG) program.
The goal of aDMG is to establish an ethical resource of ancient and historical human DNA (aDNA) data to advance studies about contemporary human traits and biology. The Coordinating Center would work with researchers and local communities to identify existing and new sources of aDNA and provide oversight and coordination of program activities across all components. Applications are not being solicited at this time.
Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO will utilize the U24 activity code. Investigators with expertise and insights into this area of ancient DNA and population genomics are encouraged to begin to consider applying for this new NOFO.
In addition, collaborative investigations combining expertise in DNA sequencing methods and technology, computational genomics and data science, human evolution, and ancient human populations will be encouraged and these investigators should also begin considering applying for this application. Link to Additional Information:[](https://www. grants.
gov/search-results-detail/359207) Grantor Contact Information:Jennifer Troyer National Human Genome Research Institute (NHGRI) #### Health & Human Services * Frequently Asked Questions ## Your session will expire in 3 minutes. To continue working, click on the "OK" button below. This is being done to protect your privacy.
Unsaved changes will be lost.
Based on current listing details, eligibility includes: Eligible applicant types: [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object], [object Object]. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Not specified Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Purpose. This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, enhance and validate translational tools to facilitate rigorous study of complementary and alternative medicine (CAM) approaches that are in wide use by the public. Recent data from the National Health Interview Survey [http://www.cdc.gov/nchs/nhis.htm] establish that Americans are utilizing CAM approaches to promote health and well-being, to treat or prevent disease, and for symptom relief. CAM approaches being widely used include massage and manipulative therapies, meditation, yoga, and acupuncture. Health conditions, particularly chronic pain, back pain and musculoskeletal pain, are the most commonly cited reasons for their use. This FOA focuses on encouraging the development of improved tools to study safety, efficacy, and clinical effectiveness of widely used CAM approaches, such as: mind-body interventions, manual therapies, yoga, and acupuncture. This FOA is not focused on tools for the study of natural products, such as herbal therapies. Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, RFA-AT-09-002, which solicits applications under the R01 grant mechanism. Funds Available and Anticipated Number of Awards. The estimated amount of funds available for support of 5 projects awarded as a result of this announcement is $1.25 million for fiscal year 2010. Future year amounts will depend on annual appropriations. Funding Opportunity Number: RFA-AT-09-004. Assistance Listing: 93.213. Funding Instrument: G. Category: HL. Award Amount: $1.3M total program funding.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
-This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for the modification or development of new screening technologies that are better able to consistently detect mild hearing loss (i.e., less than 40 dB Hearing Level or 40 dB HL) in one or both ears in infants and young children without significantly increasing the number of false positives (i.e., those who fail the screen but do not have hearing loss). -The Early Hearing Detection and Intervention (EHDI) program within the National Center for Birth Defects and Developmental Disabilities (NCBDDD) of the Centers for Disease Control and Prevention (CDC) and the National Institute on Deafness and Other Communication Disorders (NIDCD), NIH, are working to ensure infants and children with mild forms of hearing loss are identified as soon as possible. Part of this effort involves having screening technology available that can reliably detect these hearing losses. -This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-06-547, that solicits applications under the Small Business Technology Transfer (STTR [R41/R42]) grant mechanisms. Note,that CDC does not accept STTR applications so is participating only in PA-06-546. Funding Opportunity Number: PA-06-546. Assistance Listing: 93.173,93.283. Funding Instrument: G. Category: HL.
NBNA Scholarship Program is a grant from National Black Nurses Association (NBNA) providing scholarships starting at $1,000 to nursing students at all levels, from LPN to Doctorate. Open to active NBNA members currently enrolled in accredited nursing programs with at least one year of schooling remaining. Over 32 scholarships totaling more than $68,000 were awarded in 2020, and over $150,000 has been distributed to PhD candidates to date. Awards are presented annually at the NBNA Institute and Conference. The 2025-2026 program cycle is currently open. Applicants must be members of a local NBNA chapter.
Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed) is sponsored by National Cancer Institute (NCI). This NOFO encourages applications promoting transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. It specifically mentions the integration of modeling and simulation approaches to guide rational nanomaterial design and the use of artificial intelligence (AI) and modeling to aid rational drug design. This directly relates to personalized medicine and cancer treatment, though the primary focus is nanotechnology.